News | Stents Drug Eluting | May 31, 2018

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial

BIO-RESORT one- to two-year landmark analysis shows significantly lower TLF and TLR rates for Orsiro compared to Resolute Integrity, with a favorable trend compared to Synergy

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial

May 31, 2018 — Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session at EuroPCR 2018, May 21-24 in Paris, France.

Results from this large-scale, three-arm trial with complex all-comers population treated with highly dissimilar contemporary drug-eluting stents (DES) confirmed the trend seen with the one-year data, supporting the use of ultrathin bioabsorbable polymer DES.

Data were presented by Dr. Marlies M. Kok, Thoraxcentrum Twente, MST, Enschede, the Netherlands and simultaneously published in EuroIntervention.

At the two-year follow-up in the BIO-RESORT trial (n=3,514), all three stents showed low target vessel failure (TVF) rates. Orsiro1 demonstrated a favorable trend without reaching statistical significance2 (Orsiro 6.6 percent, Synergy3 6.8 percent, Resolute Integrity4 8.3 percent).

The landmark analysis2 evaluating the incremental events between the first and second year of follow-up showed patients in the Orsiro arm with significantly lower rates of target lesion failure (TLF) in comparison to the permanent-polymer DES arm (respectively Orsiro 1.1 percent, Resolute Integrity 2.4 percent p=0.02) and numerically lower than in the biodegradable-polymer DES Synergy arm (Synergy 1.6 percent, Resolute Integrity 2.4 percent p=0.22). Furthermore, the landmark analysis demonstrated that Orsiro achieved the lowest rate of TLR beyond one year across all arms (respectively Orsiro 0.6 percent, Resolute Integrity 1.5 percent p=0.04; Synergy 0.9 percent, Resolute Integrity 1.5 percent p=0.18).

The investigators noted that “very thin-strut biodegradable polymers DES have flexible designs and refined coatings to promote re-endothelialization and reduce the risk of ischemic coronary events.” They also noted that “given those signals seen from the landmark analysis, the ultrathin 60 micron5 bioabsorbable polymer Orsiro DES might reduce the risk of repeat revascularization after the first year of follow-up.”

This data is in line with previously presented BIOFLOW-V6 results demonstrating significantly better outcomes for Orsiro compared to a permanent polymer DES (Xience7).

Read the February 2019 article FDA Clears Biotronik Orsiro Stent That Outperforms Xience

For more information: www.biotronik.com


Related Content

News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
Subscribe Now